Hengrui Pharma

MADRID – October 29, 2026 -- Hengrui Pharma presented a record 64 oncology studies at the ESMO Congress 2026 in Madrid. Innovative oncology medicines generated 81.02% of the company's innovative medicine sales revenue in 2025.

Hengrui lists 64 accepted studies across 21 drugs

The accepted work comprises three Proffered Papers, three Rapid Oral presentations, 32 Posters and 26 e-Posters. The studies span more than ten cancer areas, including gastrointestinal, lung, breast, gynecological and genitourinary cancers, plus supportive care. They involve 21 innovative drugs in China: nine approved products and 12 investigational candidates.

Hengrui has attended ESMO for 11 consecutive years since 2016. It has presented nearly 200 research findings at the congress since 2023.

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.

Novo secures global rights excluding Greater China

Under the agreement, Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 worldwide, excluding the Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan Region. Hengrui Pharma retains eligibility for royalties on net sales of the drug within Novo's licensed territory, on top of the milestone-based payments tied to development, regulatory and commercial targets.